Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Topotecan Combined With Anlotinib in Platinum-resistant Recurrent Ovarian Cancer
NCT05736952Phase 2Withdrawn
- Sponsor
- Xinhua Hospital
- Start
- Mar 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in ovarian cancer, sponsored by Xinhua Hospital. Planned start Mar 2023; status: withdrawn.
02
Drugs
anlotinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05736952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736952.